T1	p 109 117	Autism .
T2	p 172 178	autism
T3	p 188 196	disorder
T4	p 199 202	ASD
T5	p 612 673	Age-matched boys with ADHD ( 15 ) , ASD ( 18 ) , and controls
T6	p 679 680	)
T7	p 947 955	patients
T8	p 965 994	drug effects . Patients under
T9	p 1121 1125	boys
T10	p 1208 1212	boys
T11	p 1349 1353	boys
T12	i 24 34	Fluoxetine
T13	i 327 356	serotonin reuptake inhibitors
T14	i 359 364	SSRIs
T15	i 700 746	functional magnetic resonance imaging ( fMRI )
T16	i 765 769	task
T17	i 818 853	acute dose of Fluoxetine or placebo
T18	i 874 892	placebo-controlled
T19	i 1077 1081	fMRI
T20	i 1107 1114	placebo
T21	i 1281 1291	Fluoxetine
T22	i 1421 1428	placebo
T23	i 1491 1501	Fluoxetine
T24	o 45 73	Prefrontal Cortex Activation
T25	o 116 158	. Attention deficit hyperactivity disorder
T26	o 211 239	brain function abnormalities
T27	o 247 268	cognitive flexibility
T28	o 1126 1176	underactivated medial prefrontal cortex ( mPFC ) ,
T29	o 1252 1330	precuneus activation . Under Fluoxetine , mPFC activation was up-regulated and
T30	o 1469 1480	performance
T31	o 1535 1550	mPFC activation
T32	o 1554 1566	ASD and ADHD
T33	o 1574 1591	reversal learning
T34	o 1605 1616	dissociated